Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.”In the company’s words, NCT04874350 on ClinicalTrials.gov
- Tested for
- Liver Cirrhosis, Sarcopenia
- Main trialPhase 2
- “This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.”In the company’s words, NCT04874350 on ClinicalTrials.gov
Other drugs for Liver Cirrhosis
- ElafibranorIpsen · Phase 3
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- Saroglitazar MagnesiumZydus Therapeutics Inc. · Phase 3
- HydronidoneBeijing Continent Pharmaceutical Co, Ltd. · Phase 3
- LinerixibatGSK · Phase 3
- SeladelparGilead (Kite) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 18 Dec 2023 | A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026